Blood glucose performance test

Submission date 17/11/2014	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 27/01/2015	Overall study status Completed	 Statistical analysis plan Results
Last Edited 09/07/2020	Condition category Nutritional, Metabolic, Endocrine	Individual participant dataRecord updated in last year

Plain English summary of protocol

Background and study aims

The aim of this study is to monitor the performance of on-market (CE marked) blood glucose monitoring systems (blood glucose meters and test strips) designed for people with diabetes to test their blood glucose, especially those people who take insulin. These systems are used as part of standard care of diabetes and are freely available to buy on the market.

Who can participate?

Patients over 16 years of age with diabetes who are willing to provide a blood sample for analysis.

What does the study involve?

You will visit a diabetes clinic or suitable outpatient clinic. The visit is expected to last about 5 to 20 minutes. You will give a blood sample either by venepuncture (the puncture of a vein) or by a fingerprick and the blood will be tested using both the blood glucose monitoring system and the reference method.

What are the possible benefits and risks of participating?

There may be no direct benefit to the subject if they decide to take part in this study. However, the information gained from the results will make an important contribution to ensuring the blood glucose monitoring systems give reliable results for people with diabetes. The risks to taking part in this study are the same as those associated with routine self-blood glucose testing or giving a blood sample. These risks are small but could include pain, bruising, local infection and fainting caused by the lancet or needle used to obtain a blood sample.

Where is the study run from?

The Diabetes Centre, Ipswich Hospital NHS Trust (UK).

When is the study starting and how long is it expected to run for? The study started in October 2014 and will finish in October 2024.

Who is funding the study? Abbott Diabetes Care Ltd (UK). Who is the main contact? Gerry Rayman

Contact information

Type(s) Scientific

Contact name Dr Gerry Rayman

Contact details The Diabetes Centre The Ipswich Hospital NHS Trust Heath Road Ipswich United Kingdom IP4 5PD

Gerry.Rayman@ipswichhospital.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers ADC-PMS-GLU-12014

Study information

Scientific Title Blood glucose performance test

Acronym NA

Study objectives

This aim of this study is to evaluate the accuracy of blood glucose monitoring systems on subjects with diabetes at the study site. The results will be evaluated by comparing results obtained using either venous whole blood obtained by venepuncture or capillary whole blood obtained from a fingerstick and then tested on the blood glucose monitoring system, to whole blood tested on the Yellow Spring Instrument (YSI analyser) reference method.

Ethics approval required

Old ethics approval format

Ethics approval(s) NRES Committee East of England - Cambridge Central, 01/11/2013, REC ref: 13/EE/0258

Study design Single-centre prospective open single-arm trial

Primary study design Interventional

Secondary study design Non randomised study

Study setting(s) Hospital

Study type(s) Diagnostic

Participant information sheet

Health condition(s) or problem(s) studied

Diabetes

Interventions

Either:

Venepuncture will be performed and venous whole blood from the subject will be tested on the blood glucose monitoring system, the HemoCue analyser and the YSI analyser as whole blood Or:

A fingerstick will be performed and capillary whole blood from the subject will be tested on the blood glucose monitoring system. The same fingerstick will be used to collect a blood sample to perform measurements on the HemoCue analyser and the YSI analyser as whole blood

Intervention Type

Device

Primary outcome measure

The accuracy of the blood glucose monitoring system compared to the YSI analyser using fingerstick capillary or venous whole blood samples

Secondary outcome measures N/A

Overall study start date 29/10/2014

Completion date 31/10/2024

Eligibility

Key inclusion criteria

1. Subjects has diabetes

2. Subject is willing to provide a whole blood sample for analysis using:

2.1. The blood glucose monitoring systems

2.2. HemoCue analyser

2.3. YSI analyser

3. The subject is able to understand the patient information sheet and sign the informed consent form prior to any clinical investigation plan directed activity

Participant type(s)

Patient

Age group

Adult

Lower age limit 16 Years

Sex

Both

Target number of participants 50 per study event

Key exclusion criteria

Subject under 16 years of age
 Subject is unwilling or unable to give consent for a blood sample to be collected

Date of first enrolment

29/10/2014

Date of final enrolment 31/10/2024

Locations

Countries of recruitment England

United Kingdom

Study participating centre

The Diabetes Centre Ipswich Hospital Heath Road Ipswich United Kingdom IP4 5PD

Sponsor information

Organisation Abbott Diabetes Care Ltd (UK)

Sponsor details

c/o Joe Bugler Range Road Witney United Kingdom OX29 0YL

Sponsor type Industry

ROR https://ror.org/03wnay029

Funder(s)

Funder type Industry

Funder Name Abbott Diabetes Care Ltd (UK)

Results and Publications

Publication and dissemination plan To be confirmed at a later date

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not expected to be made available

Study outputs Output type HRA research summary

Details Date created

Date added 28/06/2023

Peer reviewed? No Patient-facing? No